SCHEMBL63653

SCHEMBL63653

CNCC1CCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1191814 1.00
SCHEMBL1192014 1.00
SCHEMBL2128830 0.93
SCHEMBL20619655 0.91 HPGD (0.46)
SCHEMBL13410720 0.87
SCHEMBL11306175 0.81 KMT2A (0.44)
SCHEMBL611743 0.80 KMT2A (0.53)
SCHEMBL10649185 0.78
SCHEMBL12201657 0.77 USP2 (0.46)
SCHEMBL2448784 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10556908-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-02-11 US claimed
US-20190106426-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2019-04-11 US claimed
US-20180360834-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INT (DE) 2018-12-20 US claimed
US-10112950-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2018-10-30 US claimed
CN-105218767-B A kind of butadiene block copolymer and preparation method thereof 中国石油化工股份有限公司 2018-07-20 CN claimed
CN-104558455-B A kind of butylbenzene copolymer and its preparation method and application 中国石油化工股份有限公司 2018-01-19 CN claimed
US-20170369497-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2017-12-28 US claimed
US-9695180-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2017-07-04 US claimed
EP-3173084-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Boehringer Ingelheim International GmbH (DE) 2017-05-31 EP claimed
US-20170112835-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INT (DE) 2017-04-27 US claimed
US-6967216-B2 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor ASTRAZENECA AB (SE) 2005-11-22 US claimed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 EP claimed
US-6822097-B1 THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS AMGEN, INC. 2004-11-23 US claimed
US-20030225097-A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor ASTRAZENECA AB (SE) 2003-12-04 US claimed
US-20030225079-A1 Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-04 US claimed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 WO claimed
EP-1278739-A1 AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR AstraZeneca AB (SE) 2003-01-29 EP claimed
US-20020173509-A1 Quinazoline derivatives and phamaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-11-21 US claimed
US-20020169180-A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-11-14 US claimed
WO-2001085714-A1 AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR ASTRAZENECA AB (SE) 2001-11-15 WO claimed